Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
Globe Newswire•03/11/2026•07:30 ET
0
Key Highlights
- ➤Ascentage Pharma (AAPG) management to attend UBS Global Biopharma Conference in London November 16
- ➤Ascentage Pharma (AAPG) management to attend Jefferies Global Healthcare Conference November 17
- ➤Olverembatinib approved in China for multiple CML indications and covered by China’s NRDL
- ➤Lisaftoclax approved in China for previously treated CLL/SLL after systemic therapy including BTK inhibitors
ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in two upcoming investor conferences in London, United Kingdom.
Format: Company presentation and one-on-one investor meetings
Get started
Create a free account to read the full story.